Synthetic Biology to Become a Major Economic Driver, Part 2 – Amy Webb : 914

Natural First-Aid Healing: https://3rdrockessentials.com, use code DAVE to save 20%

Non-Tobacco Nicotine Alternative: https://lucy.co, use code DAVE20 to get 20% off your first order of pouches, gums, or lozenges

Biostack for High Performance: https://vatellia.com, use code DAVE2022 to save 10% or subscribe and save 15% + receive a free bottle of Kale Buster

IN THIS EPISODE OF THE HUMAN UPGRADE™...

… you’ll get a look at synthetic biology (SYNBIO) through the lens of quantitative futurist Amy Webb in Part 2 of a special two-part episode. The Part 1 episode #913 explores the scientific perspective with microbiologist and geneticist Andrew Hessel.

Amy and Andrew recently authored, “The Genesis Machine: Our Quest to Rewrite Life in the Age of Synthetic Biology.” SYNBIO is the promising and controversial technology platform that combines biology and artificial intelligence. Amy investigates what SYNBIO means for people, commerce and the planet. 

“This is a book about science,” Amy describes, “but I did not want to write a science book. This is also a business book. It's an understanding-your-own-body book.”

She’s a futurist who works with data and does predictive modeling. Her academic background includes game theory and economics

Amy founded the Future Today Institute to help companies understand the forces that will shape their futures. She’s a professor of strategic foresight at the NYU Stern School of Business and a Visiting Fellow at Oxford University’s Säid School of Business. She writes extensively about biotechnology, artificial intelligence, technology policy, and business strategy.

“This emerging field of science—synthetic biology—promises to reveal how life is created and how it can be recreated, for many varied purposes, as explained in “The Genesis Machine:”

• to help us heal without prescription medications, 
• to grow meat without harvesting animals, and 
• to engineer our families when nature fails us.

With SYNBO developments come a slew of considerations about how to manage it responsibly.

“For the most part, in the US, the regulation is on the end product,” Amy says. “Nobody wants to regulate the process, because we don't want to hamper innovation. However, it does start to raise some gnarly questions when we're talking about alternative uses or different uses for some of these technologies, or cross-border use.”

“There's some alignment globally on what's called germline editing, which is when you edit the genome to make it heritable. So whatever that is passes on. At the moment, just about 190 countries have aligned [to agree] that they don't want that to happen. But outside of that, there's a lot of confusion.”

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.